Zev M Nakamura1, Rebekah P Nash2, Laura J Quillen2, Daniel R Richardson3, Rebecca C McCall4, Eliza M Park5. 1. Department of Psychiatry, University of North Carolina - Chapel Hill, Chapel Hill, NC. Electronic address: zev.nakamura@unchealth.unc.edu. 2. Department of Psychiatry, University of North Carolina - Chapel Hill, Chapel Hill, NC. 3. Lineberger Comprehensive Cancer Center, University of North Carolina - Chapel Hill, Chapel Hill, NC; The Cecil G. Sheps Center for Health Services Research, University of North Carolina - Chapel Hill, Chapel Hill, NC. 4. Health Sciences Library, University of North Carolina - Chapel Hill, Chapel Hill, NC. 5. Department of Psychiatry, University of North Carolina - Chapel Hill, Chapel Hill, NC; Lineberger Comprehensive Cancer Center, University of North Carolina - Chapel Hill, Chapel Hill, NC; Department of Medicine, University of North Carolina - Chapel Hill, Chapel Hill, NC.
Abstract
BACKGROUND: Patients with cancer frequently experience neuropsychiatric symptoms due to their medical illness or its treatment. In recent decades, psychiatrists have become increasingly involved in the care of patients with cancer. However, psychiatrists may be less familiar with hematopoietic stem cell transplantation (HSCT), a distinct cancer treatment modality associated with multiple neuropsychiatric sequelae. OBJECTIVE: To provide an overview of HSCT, and describe the prevalence, impact, risk factors, and suggested management of psychiatric consequences of HSCT. METHODS: We performed literature searches in PubMed and PsychInfo to identify articles describing neuropsychiatric symptoms, including depression, anxiety, distress, post-traumatic stress disorder, delirium and cognitive impairment, resulting from HSCT in adults. Those articles most relevant to this manuscript were included. RESULTS: Psychiatrists may be involved in the treatment of patients before, during, or after inpatient hospitalization for HSCT. Each phase of treatment introduces unique stressors that may lead to or exacerbate psychiatric disorders. Appropriate management requires evaluation of HSCT-related medications, an understanding of the impact of complications from HSCT, and consideration of how the patient's underlying medical condition should influence psychiatric recommendations. CONCLUSION: To optimize patient outcomes, consulting psychiatrists should be familiar with the basic principles of HSCT, and the neuropsychiatric sequelae that may result from treatment. Further research is needed to identify strategies to manage psychiatric complications in this unique population.
BACKGROUND:Patients with cancer frequently experience neuropsychiatric symptoms due to their medical illness or its treatment. In recent decades, psychiatrists have become increasingly involved in the care of patients with cancer. However, psychiatrists may be less familiar with hematopoietic stem cell transplantation (HSCT), a distinct cancer treatment modality associated with multiple neuropsychiatric sequelae. OBJECTIVE: To provide an overview of HSCT, and describe the prevalence, impact, risk factors, and suggested management of psychiatric consequences of HSCT. METHODS: We performed literature searches in PubMed and PsychInfo to identify articles describing neuropsychiatric symptoms, including depression, anxiety, distress, post-traumatic stress disorder, delirium and cognitive impairment, resulting from HSCT in adults. Those articles most relevant to this manuscript were included. RESULTS: Psychiatrists may be involved in the treatment of patients before, during, or after inpatient hospitalization for HSCT. Each phase of treatment introduces unique stressors that may lead to or exacerbate psychiatric disorders. Appropriate management requires evaluation of HSCT-related medications, an understanding of the impact of complications from HSCT, and consideration of how the patient's underlying medical condition should influence psychiatric recommendations. CONCLUSION: To optimize patient outcomes, consulting psychiatrists should be familiar with the basic principles of HSCT, and the neuropsychiatric sequelae that may result from treatment. Further research is needed to identify strategies to manage psychiatric complications in this unique population.
Authors: Areej El-Jawahri; Lara Traeger; Joseph A Greer; Harry VanDusen; Sarah R Fishman; Thomas W LeBlanc; William F Pirl; Vicki A Jackson; Jason Telles; Alison Rhodes; Zhigang Li; Thomas R Spitzer; Steven McAfee; Yi-Bin A Chen; Jennifer S Temel Journal: J Clin Oncol Date: 2017-09-19 Impact factor: 44.544
Authors: Allison J Applebaum; Katherine N DuHamel; Gary Winkel; Christine Rini; Paul B Greene; Catherine E Mosher; William H Redd Journal: J Consult Clin Psychol Date: 2012-04-02
Authors: Leigh J Beglinger; Kevin Duff; Sara Van Der Heiden; Karen Parrott; Douglas Langbehn; Roger Gingrich Journal: Biol Blood Marrow Transplant Date: 2006-09 Impact factor: 5.742
Authors: Angela Scherwath; Lena Schirmer; Margitta Kruse; Gundula Ernst; Matthias Eder; Andreas Dinkel; Sabine Kunze; Friedrich Balck; Martin Bornhäuser; Gerhard Ehninger; Karin Dolan; Martin Gramatzki; Hans-Jochem Kolb; Pia Heußner; Hans Wilhelm; Dietrich W Beelen; Frank Schulz-Kindermann; Axel R Zander; Uwe Koch; Anja Mehnert Journal: Psychooncology Date: 2012-09-04 Impact factor: 3.894
Authors: Zev M Nakamura; Allison M Deal; Donald L Rosenstein; Laura J Quillen; Stephanie A Chien; William A Wood; Thomas C Shea; Eliza M Park Journal: Contemp Clin Trials Date: 2020-06-30 Impact factor: 2.226
Authors: Zev M Nakamura; Allison M Deal; Eliza M Park; Laura J Quillen; Stephanie A Chien; Kate E Stanton; Sean D McCabe; Hillary M Heiling; William A Wood; Thomas C Shea; Donald L Rosenstein Journal: J Psychosom Res Date: 2021-04-27 Impact factor: 4.620